Cumberland Pharmaceuticals Inc Total Assets

Latest as of June 2026: $62.88 Million USD

Cumberland Pharmaceuticals Inc total assets. Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) holds total assets worth $62.88 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CPIX market cap for the company's overall valuation and market capitalisation.

Total Assets of Cumberland Pharmaceuticals Inc (2005–2025)

Total assets of Cumberland Pharmaceuticals Inc from 2005 to 2025. This chart illustrates how Cumberland Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See CPIX stock price and chart for real-time trading data and today's change.

Cumberland Pharmaceuticals Inc - Asset Composition Analysis

Cumberland Pharmaceuticals Inc Total Assets Breakdown (December 2025)

Cumberland Pharmaceuticals Inc total assets breakdown as of December 2025. Cumberland Pharmaceuticals Inc's total assets of $62.88 Million consist of 48.2% current assets and 51.8% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 14.9%
Accounts Receivable $16.94 Million 22.1%
Inventory $6.23 Million 8.1%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $14.03 Million 18.3%
Goodwill $914.00K 1.2%

Asset Composition Trend (2005–2025)

This chart illustrates how Cumberland Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cumberland Pharmaceuticals Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Cumberland Pharmaceuticals Inc's current assets represent 48.2% of total assets in 2025, a decrease from 84.5% in 2005.
  • Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, down from 54.4% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2005.
  • Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.

Cumberland Pharmaceuticals Inc Competitors by Total Assets

Key competitors of Cumberland Pharmaceuticals Inc based on total assets are shown below.

Company Country Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
China CN¥9.54 Billion
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
China CN¥6.44 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Bide Pharmatech Co. Ltd. A
SHG:688073
China CN¥2.54 Billion
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
China CN¥4.69 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥25.73 Billion

Cumberland Pharmaceuticals Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.96 1.30 2.63
Quick Ratio 0.96 1.17 2.06
Cash Ratio 0.00 0.00 0.00
Working Capital $-1.55 Million $7.23 Million $29.27 Million

Cumberland Pharmaceuticals Inc - Advanced Valuation Insights

This section examines the relationship between Cumberland Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.57
Latest Market Cap to Assets Ratio 0.84
Asset Growth Rate (YoY) 1.6%
Total Assets $76.82 Million
Market Capitalization $64.58 Million USD

Valuation Analysis

Near Book Valuation: The market values Cumberland Pharmaceuticals Inc's assets close to their book value (0.84x), suggesting investors view the company's assets at approximately fair value.

Positive Asset Growth: Cumberland Pharmaceuticals Inc's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Cumberland Pharmaceuticals Inc (2005–2025)

The table below shows the annual total assets of Cumberland Pharmaceuticals Inc from 2005 to 2025.

Year Total Assets Change
2025-12-31 $76.82 Million +1.64%
2024-12-31 $75.58 Million -7.57%
2023-12-31 $81.78 Million -12.00%
2022-12-31 $92.93 Million +10.02%
2021-12-31 $84.46 Million -12.44%
2020-12-31 $96.46 Million -7.73%
2019-12-31 $104.55 Million -7.23%
2018-12-31 $112.69 Million +20.87%
2017-12-31 $93.23 Million -0.18%
2016-12-31 $93.40 Million +1.62%
2015-12-31 $91.92 Million -3.65%
2014-12-31 $95.41 Million +8.89%
2013-12-31 $87.61 Million -11.14%
2012-12-31 $98.59 Million +3.22%
2011-12-31 $95.52 Million +3.76%
2010-12-31 $92.05 Million -11.25%
2009-12-31 $103.72 Million +233.31%
2008-12-31 $31.12 Million +7.61%
2007-12-31 $28.92 Million +9.20%
2006-12-31 $26.48 Million +160.30%
2005-12-31 $10.17 Million --

About Cumberland Pharmaceuticals Inc

NASDAQ:CPIX USA Drug Manufacturers - Specialty & Generic
Market Cap
$64.58 Million
Market Cap Rank
#20701 Global
#4699 in USA
Share Price
$4.31
Change (1 day)
+2.13%
52-Week Range
$1.90 - $8.97
All Time High
$8.97
About

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more